Findings

What do systematic reviews say?

670 questions · 686 findings · 338 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 349 · 50.9%GRADE not reported 70 · 10.2%Very low 75 · 10.9%Low 75 · 10.9%Moderate 87 · 12.7%High 30 · 4.4%

Minoxidil vs placebo

Change in quality of life · women with FPHL

1 finding from 1 review

Interventions for female pattern hair loss 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 260 participants
Low

Topical antibiotics vs another topical antibiotic or placebo

Quality of life at 1 month · children and adults with corneal abrasion

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic prophylaxis for corneal abrasion 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Casirivimab/imdevimab vs placebo

Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

The review found no eligible studies for this question.

2 findings from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bamlanivimab vs placebo

Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tixagevimab/cilgavimab vs placebo

Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antibiotics vs placebo or no intervention

Quality of life at maximum · patients with coronary heart disease

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotics for secondary prevention of coronary heart disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Compression stockings vs no treatment or placebo stockings

Quality of life (3 months) · people with varicose veins without venous ulceration

1 finding from 1 review

Graduated compression stockings for the initial treatment of varicose veins in people without venous ulceration 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

Azithromycin vs placebo or usual care

Quality of life at longest · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

1 finding from 1 review

Antibiotics for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Azithromycin vs placebo or usual care

Quality of life at longest · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…

1 finding from 1 review

Antibiotics for the treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Beta‐blockers vs placebo or no intervention

Quality of life at maximum · patients with suspected or diagnosed myocardial infarction

The review found no eligible studies for this question.

1 finding from 1 review

Beta‐blockers for suspected or diagnosed acute myocardial infarction 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Quality of life at 3 months · adults experiencing acute traumatic stress symptoms

1 finding from 1 review

Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Very low

Fluvoxamine plus standard care vs placebo + standard care

Quality of life at longest · symptomatic people with COVID‐19

The review found no eligible studies for this question.

1 finding from 1 review

Fluvoxamine for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Electrical stimulation vs Placebo / sham solution

OAB‐related quality of life · Adults with overactive bladder (OAB)

1 finding from 1 review

Electrical stimulation with non‐implanted electrodes for overactive bladder in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 627 participants
Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

Quality of life: total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

Quality of life: total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ triple therapy: VX‐440‐tezacaftor‐ivacaftor vs placebo

Quality of life: total score · adults with cystic fibrosis and with the F508del/MF genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ triple therapy: VX‐152‐tezacaftor‐ivacaftor vs placebo

Quality of life: total score · adults with cystic fibrosis and with the F508del/MF genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Quality of life: total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

TENS vs sham TENS

Quality of life measurements · children aged 3 to 18 years with daytime urinary incontinence

The review found no eligible studies for this question.

1 finding from 1 review

Conservative interventions for treating functional daytime urinary incontinence in children 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolides vs placebo

Quality of life not reported · children with bronchiectasis

The review found no eligible studies for this question.

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found